Importantly, blockade of α4β7 or MAdCAM-1 reduces the recruitment of CD4 T cells into the intestine and NASH liver and attenuates hepatic inflammation and fibrosis (67). Here, MADCAM1 is linked to metabolic dysfunction-associated steatohepatitis.